1. Home
  2. KZIA vs RNA Comparison

KZIA vs RNA Comparison

Compare KZIA & RNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Kazia Therapeutics Limited

KZIA

Kazia Therapeutics Limited

SELL

Current Price

$5.61

Market Cap

125.6M

Sector

Health Care

ML Signal

SELL

Logo Avidity Biosciences Inc.

RNA

Avidity Biosciences Inc.

SELL

Current Price

$6.45

Market Cap

141.3M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
KZIA
RNA
Founded
1994
2025
Country
Australia
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
125.6M
141.3M
IPO Year
2002
2025

Fundamental Metrics

Financial Performance
Metric
KZIA
RNA
Price
$5.61
$6.45
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
9
5
Target Price
★ $28.76
$22.00
AVG Volume (30 Days)
167.6K
★ 205.6K
Earning Date
11-27-2026
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$104.53
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.86
$7.47
52 Week High
$17.40
$73.06

Technical Indicators

Market Signals
Indicator
KZIA
RNA
Relative Strength Index (RSI) 26.35 24.72
Support Level $4.86 N/A
Resistance Level $14.85 $8.50
Average True Range (ATR) 0.68 0.42
MACD -0.10 -0.09
Stochastic Oscillator 2.75 1.49

Price Performance

Historical Comparison
KZIA
RNA

About KZIA Kazia Therapeutics Limited

Kazia Therapeutics Ltd is a biotechnology company focused on pharmaceutical drug development in oncology. The company has a portfolio of development candidates across various technologies targeting multiple cancer indications. Its primary program is Paxalisib, an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, designed for the treatment of brain cancer. The company develops targeted therapies aimed at addressing medical needs in oncology. The company operates in Australia and the United States.

About RNA Avidity Biosciences Inc.

Atrium Therapeutics Inc is a biopharmaceutical firm focused on developing RNA-based therapeutics for cardiac conditions, including cardiomyopathies. Its platform technology is designed to enable targeted delivery of RNA therapeutics to heart tissue by combining ligand-based targeting approaches with oligonucleotide-based therapies. The company's development pipeline includes programs targeting genetically associated forms of cardiomyopathy, specifically involving the PRKAG2 and PLN genes.

Share on Social Networks: